Mult Scler. 2021 Sep;27(10):1615-1619. doi: 10.1177/1352458520978354. Epub 2021 Feb 2.
Little information is available regarding the incidence and clinical outcome of the SARS-CoV2 infection in patients with multiple sclerosis (pwMS).
To determine the incidence, clinical outcome, and impact of COVID-19 on pwMS.
This observational study was prospectively performed on a cohort of pwMS ( = 11,560) followed up by 47 out of 51 Brazilian MS referral centers that registered pwMS with COVID-19 at the REDONE platform from 13 March to 4 June 2020.
The incidence of COVID-19 for pwMS patients was 27.7/10,000 patients and for the general population was 29.2/10,000 inhabitants. A total of 94 (77 women) pwMS patients, aged 40 ± 10.25 years, presenting 9.9 ± 8.6 years of MS disease duration, developed the COVID-19, most of them (87%) exhibited the mild form of the disease. Eighty (96%) patients maintained the use of MS disease-modifying treatment (DMT) during COVID-19 pandemic and 14 patients were not in use of DMTs.
Incidence of COVID-19 in Brazilian pwMS was not different from those observed for the general Brazilian population. Most pwMS exhibited mild COVID-19, despite the maintenance of the underlying MS treatment.
关于多发性硬化症患者（pwMS）感染新型冠状病毒2（SARS-CoV-2）的发病率和临床结果，目前可用信息较少。
确定2019冠状病毒病（COVID-19）在pwMS中的发病率、临床结果及影响。
本观察性研究对一组pwMS患者（n = 11560）进行了前瞻性研究，该组患者由巴西51个多发性硬化症转诊中心中的47个进行随访，这些中心于2020年3月13日至6月4日在REDONE平台上登记了患有COVID-19的pwMS患者。
pwMS患者中COVID-19的发病率为27.7/10000例患者，普通人群的发病率为29.2/10000居民。共有94例（77名女性）pwMS患者，年龄40±10.25岁，多发性硬化症病程9.9±8.6年，感染了COVID-19，其中大多数（87%）表现为轻症。80例（96%）患者在COVID-19大流行期间继续使用多发性硬化症疾病修正治疗（DMT），14例患者未使用DMT。
巴西pwMS中COVID-19的发病率与巴西普通人群的发病率无差异。尽管维持基础的多发性硬化症治疗，但大多数pwMS患者表现为轻症COVID-19。
